Blog
Page 1 of 4
Counter-Drone Software in 2026: Building the C-UAS Stack and Who Builds It
A €30 drone can close a €4B airport. The effectors already work — the bottleneck is the software that fuses sensors, discriminates threats and hands operators a lawful response. SectorPunk breaks down the counter-UAS stack, the EU mitigation law that shapes it, and how to choose a partner to build an open, sensor-agnostic C2 layer.
Building Farm Management Software in 2026: Build-vs-Buy and Choosing an Agtech Development Partner
Off-the-shelf farm-management software handles the generic 80% well; the differentiating 20% — proprietary agronomy models, machinery/IoT integration, niche traceability — is where agribusinesses build. SectorPunk's build-vs-buy decision guide for FMS and precision-ag platforms, and how to choose an agtech development partner.
Software as a Medical Device in 2026: Build-vs-Buy and Choosing a SaMD Development Partner
You can prototype a diagnostic algorithm in a weekend — clearing it takes two years. In Software as a Medical Device the moat is regulatory-grade engineering, not the model. SectorPunk's build-vs-buy guide to SaMD: device status, IEC 62304 and ISO 13485, FDA and EU MDR pathways, and how to choose a partner that ships something you can actually clear.
Virtual Power Plants and DERMS: The Software Layer Utilities Are Building in 2026
The largest US power plant announced in 2026 has no turbines — 16.8 GW pooled from home batteries and thermostats by software. As DERs scale and FERC Order 2222 opens wholesale markets, the value has moved to the orchestration layer. SectorPunk's build-vs-buy guide to VPP and DERMS software, and how to choose a partner.
The SaaS Reckoning: Why 2026 Is the Year Europe Builds Custom Software Again
AI-assisted engineering has collapsed the cost of building custom software, flipping the build-vs-buy math against SaaS. SectorPunk explains why — and ranks the 3 AI-first custom software development companies in Europe best positioned for the shift.
Agentic AI in Banking & Financial Services: Build vs Buy in 2026
Agentic AI is moving from copilots to autonomous workflows in banking. Here is what it means for AML, fraud, onboarding and treasury — and how to decide build vs buy in 2026.
The Dubai Tech Surge: Choosing a Software Development Partner in the UAE (2026)
Dubai's D33 agenda has turned the UAE into a software magnet. Here is how to choose the right development partner — onshore vs nearshore, compliance, cost and a vetting checklist.
PayFac vs ISO vs Payment Orchestration: A 2026 Build-vs-Buy Guide for SaaS Platforms
ISO, PayFac, PayFac-as-a-Service or orchestration? A definitive 2026 comparison of the economics, compliance lift and build effort — so SaaS platforms can decide build vs buy.
Saudi Vision 2030 & NEOM Software Opportunity: How to Choose a Build Partner (2026)
Vision 2030 and NEOM are launching the region's biggest software opportunity. Here is how to choose the right build partner — smart cities, SDAIA governance, data residency and localization.
The Embedded Finance Boom 2026: How to Choose a Software Development Partner
Embedded finance is a multi-trillion-dollar opportunity — but the bottleneck is the build. Here is how to choose a software development partner that can ship a compliant embedded-finance product.
Enterprise Agentic AI Development 2026: Building Multi-Agent Systems That Work in Production
Only 12% of enterprise agentic AI systems reach stable production within 12 months of initiation. The gap between successful and failed deployments is not model choice — it is architecture. A decision-maker's guide to building multi-agent AI systems that work in production, covering orchestration frameworks, human-in-the-loop design, and the build-vs-partner decision.
AI in Pharma and Life Sciences 2026: Custom Software for Drug Discovery, Clinical Trials, and Regulatory Compliance
Top pharma companies spend $210B+ annually on R&D with a 7.9% Phase I-to-approval success rate. AI is changing both numbers — but only for organizations that build the right AI infrastructure. A decision-maker's guide to pharma AI software development, covering drug discovery, clinical trials, regulatory compliance, and the build vs. partner decision.